Hafsa Abbas's research while affiliated with The University of Warwick and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (4)
Background
Tumor glycolysis is a target for cancer chemotherapy. Methylglyoxal (MG) is a reactive metabolite formed mainly as a by-product in anaerobic glycolysis, metabolized by glyoxalase 1 (Glo1) of the glyoxalase system. We investigated the role of MG and Glo1 in cancer chemotherapy related in multidrug resistance (MDR).
Methods
Human Glo1 was...
The global pandemic of COVID-19 disease caused by infection with the SARS-CoV-2 coronavirus, has produced an urgent requirement and search for improved treatments while effective vaccines are developed. A strategy for improved drug therapy is to increase levels of endogenous reactive metabolites for selective toxicity to SARS-CoV-2 by preferential...
There is an urgent requirement for improved treatments of COVID-19 disease. A strategy for chemotherapy is to increase levels of endogenous reactive metabolites — such as reactive oxygen species and arginine-directed glycating agent, methylglyoxal — for selective toxicity to SARS-CoV-2. Sequence analysis of functional domains in the SARS-CoV-2 prot...
Citations
... The lead compound is a cell-permeable prodrug diester of the Glo1 inhibitor, S-p-bromobenzylglutathione cyclopentyl diester (BBGD) [28]. BBGD antitumor activity was enhanced 60-fold in hypoxia, where increased anerobic glycolysis is associated with the increased formation of MG [29,30]. An increase in cellular MG to cytotoxic levels was also involved in the mechanism of action of multiple classes of clinical antitumor drugs: DNA alkylators-mechlorethamine and mitomycin C; topoisomerase inhibitorscamptothecin, doxorubicin, and etoposide; antitubulins-paclitaxel and vincristine; and an antimetabolite, methotrexate. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/378772235800576-1467317746090_Q64/Mingzhan-Xue.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/725077372973066-1549883325706_Q64/Paul-Thornalley.jpg)
... To accomplish this task, the SARS-CoV-2 virus exploits arginine, a unique amino with side chains capable of piercing cell membranes [103,104]. For example, the S antigen of the SARS-CoV-2 virus contains a polybasic cleavage motif, "Proline-Arginine-Arginine-Alanine (PRRA)", in which the bi-arginine forms a pore in the cell membrane, initiating fusion [105]. Aside from utilizing arginine, the SARS-CoV-2 virus also activates HERVs, providing additional fusogens-a "plan B"-for ensuring viral entry [34]. ...
... Honey may inhibit SARS-CoV2 proteases as some compounds of honey may be able to bind SARSCoV-2 protease 197 . Methylglyoxal (MGO) modification might be involved in SARS-CoV-2 replication 198 . MGO is a component of manuka honey that can inhibit enveloped virus growth, viral transcription, and translation 199 . ...
... The U.S. Food and Drug Administration (FDA) recently revoked its Emergency Use Authorization (EUA) to treat COVID-19 [187]. Other drugs include the anti-HIV drugs Lopinavir-Ritonavir in combination with Ribavirin [188][189][190], tumor chemotherapy drugs, doxorubicin and paclitaxel [191], traditional herbal medicines [192], broad spectrum antiviral drug Niclosamide [193], Janus-associated kinase (JAK) 1 and 2 inhibitor, Ruxolitinib [194], anti-influenza drug Favipiravir [195], antiviral drug Remdesivir [196][197][198], and most recently, a commonly used steroid, dexamethasone [199]. Many of these drugs primarily target the RdRp (NSP12) or the main protease, M pro . ...
